« Back
Home /
Vatalanib (dihydrochloride)

Vatalanib (dihydrochloride)

Item no.	HY-12018-100mg
Manufacturer	MedChem Express
CASRN	212141-51-0
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Hepatic Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.68
Citations	[1]Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8\|[2]Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18(2), 589-596.\|[3]Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016 Mar;35(3):1297-308. Bioact Mater. 2 January 2022.\|Br J Pharmacol. 2019 Sep;176(17):3143-3160. \|Evid-Based Compl Alt. 2021 Apr 27.\|JCI Insight. 2024 May 22;9(10):e166402.\|Kitazato Graduate School of Pharmaceutical Sciences. Kitasato University. 2017.\|Oncol Rep. 2016 Mar;35(3):1297-308.\|Oxid Med Cell Longev. 18 Jul 2022.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Ulm University. 2023 Mar 21.\|Drug Metab Pharmacokinet. 2017 Jun;32(3):179-188. \|Int J Mol Sci. 2024 Nov 15;25(22):12277.\|J Microbiol Biotechnol. 2015 Aug;25(8):1227-33. \|J Pharm Anal. 2023 Sep 11.\|Patent. US20170349880A1.
Smiles	ClC1=CC=C(C=C1)NC2=NN=C(C3=C2C=CC=C3)CC4=CC=NC=C4.[H]Cl.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PTK787 (dihydrochloride),ZK-222584 (dihydrochloride),CGP-797870 (dihydrochloride)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; VEGFR
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	419.73
Product Description	Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic; warming; heat to 80°C)\|H2O: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Protein Tyrosine Kinase/RTK
Isoform	VEGFR2/KDR/Flk-1
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12018-100mg-safety-datasheet.pdf